Глобальный рынок решений по безопасности лекарственных средств и фармаконадзора – тенденции отрасли и прогноз до 2031 года

Анализ и размер рынка решений по безопасности лекарственных средств и фармаконадзора

Несколько факторов, включая растущую распространенность побочных реакций на лекарства и растущий спрос на эффективные системы мониторинга безопасности лекарств, стимулируют рынок решений по безопасности лекарств и фармаконадзора. Рынок также подпитывается растущими инвестициями крупных фармацевтических компаний в разработку лекарств и растущим принятием услуг фармаконадзора регулирующими органами для обеспечения общественной безопасности. Более того, появляющиеся передовые технологии, такие как искусственный интеллект и аналитика больших данных, еще больше стимулируют рост рынка.

Объем мирового рынка решений по безопасности лекарственных средств и фармаконадзора оценивался в 8,39 млрд долларов США в 2023 году и, по прогнозам, достигнет 14,96 млрд долларов США к 2031 году со среднегодовым темпом роста 7,5% в прогнозируемый период с 2024 по 2031 год. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ линейки продуктов, анализ цен и нормативно-правовую базу.

Область отчета и сегментация рынка       

Market Definition

Drug safety solutions and pharmacovigilance refer to practices and systems implemented by pharmaceutical companies and regulatory agencies to monitor and ensure the safety of drugs. Pharmacovigilance involves detecting, assessing, understanding, and preventing adverse effects or any other drug-related problems. It aims to improve patient safety and public health by identifying and evaluating the risks associated with pharmaceutical products throughout their lifecycle, from pre-market clinical trials to post-market surveillance.      

Drug Safety Solutions and Pharmacovigilance Market Dynamics

Drivers

• Increasing Prevalence of Adverse Drug Reactions

As the use of pharmaceuticals continues to increase, so does the likelihood of ADRs, necessitating robust pharmacovigilance systems to monitor and manage these risks effectively. With more complex and personalized treatments becoming common, the importance of pharmacovigilance in ensuring patient safety and drug efficacy is increasing. The rising incidence of adverse drug reactions (ADRs) globally is a significant driver for the drug safety solutions and pharmacovigilance market.

• Growing Demand for Personalized Medicine

Personalized medicine requires monitoring patient responses to tailor treatments, highlighting the importance of robust pharmacovigilance systems. As personalized medicine becomes more mainstream, pharmacovigilance will play a crucial role in identifying and managing individualized risks associated with these treatments. This shift towards personalized medicine, driven by advancements in genomics and biomarker research, drives the need for more comprehensive pharmacovigilance strategies and market growth.

Opportunities

• Expansion of Pharmacovigilance Outsourcing

The expansion of pharmacovigilance outsourcing refers to the increasing trend among pharmaceutical companies to delegate pharmacovigilance activities to external service providers. As pharmaceutical companies face growing regulatory requirements and the need for specialized expertise in pharmacovigilance, they opt to outsource these functions to third-party service providers. This allows companies to access specialized knowledge and resources while reducing operational costs. Outsourcing pharmacovigilance tasks is expected to grow rapidly, offering new opportunities for market growth.

• Integration of Real-World Data

Integrating real-world data (including electronic health records, claims data, and patient registries, can provide valuable insights into drug safety and effectiveness in real-world settings. By leveraging RWD, pharmacovigilance professionals can enhance signal detection, improve risk assessment, and optimize post-marketing surveillance, leading to more efficient and effective pharmacovigilance practices and creating new opportunities for the market.

Restraints/Challenges

• Regulatory Compliance and Reporting Burden

Regulatory requirements for pharmacovigilance are becoming more complex and stringent, requiring companies to invest significant resources in compliance efforts. This includes the timely and accurate reporting of adverse drug reactions (ADRs), maintaining comprehensive pharmacovigilance systems, and ensuring compliance with evolving regulations across different regions. Failure to comply with these requirements can lead to regulatory sanctions, fines, and reputational damage, posing a significant challenge to the market.

• Data Quality and Integration

Pharmacovigilance relies heavily on collecting, analyzing, and interpreting vast amounts of data from diverse sources, including clinical trials, post-market surveillance, and real-world evidence. Ensuring this data's quality, consistency, and reliability is critical for effective pharmacovigilance practices. However, data quality issues, such as incomplete or inaccurate reporting, data silos, and lack of standardization, can hinder the ability of companies to derive meaningful insights from their data and effectively identify and manage drug safety risks. The quality and integration of data is a major challenge for the market.

This drug safety solutions and pharmacovigilance market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug safety solutions and pharmacovigilance market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Drug Safety Solutions and Pharmacovigilance Market Scope

The drug safety solutions and pharmacovigilance market is segmented on the basis of type, product, functionality, end user, delivery, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Software
• Services

 Product

• Standard Form
• Customized Form

Functionality

• Adverse Event Reporting Software
• Drug Safety Audits Software
• Issue Tracking Software

 Delivery

• On-Premise Delivery Mode
• On-Demand/Cloud-Based (SAAS) Delivery Mode

 End Users

• Biotechnology and Pharmaceuticals
• Contract Research Organizations (CROS)
• Hospitals
• KPOs/BPOs
• Healthcare Providers

 Distribution Channel

• Direct Sales
• Retail Sales

Drug Safety Solutions and Pharmacovigilance Market Regional Analysis/Insights

The drug safety solutions and pharmacovigilance market is analyzed and market size insights and trends are provided by country, type, product, functionality, end user, delivery, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the market due to the escalating rates of drug abuse and adverse drug reactions.  Major regional pharmaceutical companies are investing significantly in new drug research, further propelling market growth. These factors, coupled with the stringent regulatory framework in North America, are driving the demand for pharmacovigilance services in the region.

Asia-Pacific is expected to witness significant growth during the forecast period due to the expanding government initiatives and investments to improve healthcare infrastructure and services. Furthermore, there is a growing awareness among patients in the region regarding the importance of pharmacovigilance in ensuring drug safety.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

Рынок решений по безопасности лекарств и фармаконадзора также предоставляет вам подробный анализ рынка для каждой страны по росту расходов на здравоохранение на капитальное оборудование, установленной базе различных видов продуктов для рынка решений по безопасности лекарств и фармаконадзора, влиянию технологий с использованием кривых жизненной линии и изменениям в сценариях регулирования здравоохранения и их влиянию на рынок решений по безопасности лекарств и фармаконадзора. Данные доступны за исторический период 2011-2021 гг.

Анализ конкурентной среды, решений по безопасности лекарственных средств и доли рынка фармаконадзора

Конкурентная среда рынка содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта, доминировании приложений. Приведенные выше данные касаются только фокуса компаний на рынке.

Некоторые из основных игроков, работающих на рынке решений по безопасности лекарственных средств и фармаконадзора:

• PPD Inc (США)
• Drug Safety Solutions Limited (США)
• C3i (США)
• Всемирные клинические испытания (США)
• Биоклиника (США)
• United Biosource LLC (США)
• Эннов (Гонконг)
• AB Cube SAS (Франция)
• Labcorp Drug Development (США)
• Accenture (Ирландия)
• ICON plc (США)
• Ergomed plc (Великобритания)
• IQVIA (США)
• Генпакт (США)
• Cognizant (США)
• Parexel International Corporation (США)
• ArisGlobal (США)

SKU-50238